Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study.
Zhang H, Rios RS, Boursier J, Anty R, Chan WK, George J, Yilmaz Y, Wong VW, Fan J, Dufour JF, Papatheodoridis G, Chen L, Schattenberg JM, Shi J, Xu L, Wong GL, Lange NF, Papatheodoridi M, Mi Y, Zhou Y, Byrne CD, Targher G, Feng G, Zheng M. Zhang H, et al. Among authors: papatheodoridi m. Chin Med J (Engl). 2023 Feb 5;136(3):341-350. doi: 10.1097/CM9.0000000000002603. Chin Med J (Engl). 2023. PMID: 36848175 Free PMC article.
Optimization and Validation of a Novel Three-Dimensional Co-Culture System in Decellularized Human Liver Scaffold for the Study of Liver Fibrosis and Cancer.
Thanapirom K, Caon E, Papatheodoridi M, Frenguelli L, Al-Akkad W, Zhenzhen Z, Vilia MG, Pinzani M, Mazza G, Rombouts K. Thanapirom K, et al. Among authors: papatheodoridi m. Cancers (Basel). 2021 Sep 30;13(19):4936. doi: 10.3390/cancers13194936. Cancers (Basel). 2021. PMID: 34638417 Free PMC article.
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Papatheodoridis GV, et al. Among authors: papatheodoridi m. Antivir Ther. 2018;23(8):677-685. doi: 10.3851/IMP3256. Antivir Ther. 2018. PMID: 30044765
Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Papatheodoridis GV, et al. Among authors: papatheodoridi m. Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261. Antivir Ther. 2018. PMID: 30091421 No abstract available.
Can we stop nucleoside analogues before HBsAg loss?
Papatheodoridi M, Papatheodoridis G. Papatheodoridi M, et al. J Viral Hepat. 2019 Aug;26(8):936-941. doi: 10.1111/jvh.13091. Epub 2019 Mar 27. J Viral Hepat. 2019. PMID: 30803099 Review.
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
Papatheodoridi M, Hiriart JB, Lupsor-Platon M, Bronte F, Boursier J, Elshaarawy O, Marra F, Thiele M, Markakis G, Payance A, Brodkin E, Castera L, Papatheodoridis G, Krag A, Arena U, Mueller S, Cales P, Calvaruso V, de Ledinghen V, Pinzani M, Tsochatzis EA. Papatheodoridi M, et al. J Hepatol. 2021 May;74(5):1109-1116. doi: 10.1016/j.jhep.2020.11.050. Epub 2020 Dec 9. J Hepatol. 2021. PMID: 33307138
52 results